Eyal Rubin
2021
In 2021, Eyal Rubin earned a total compensation of $836.8K as Senior Vice President, Chief Financial Officer at Protalix BioTherapeutics, a 9% decrease compared to previous year.
Compensation breakdown
| Option Awards | $21,062 |
|---|---|
| Salary | $325,101 |
| Stock Awards | $385,201 |
| Other | $105,460 |
| Total | $836,824 |
Rubin received $385.2K in stock awards, accounting for 46% of the total pay in 2021.
Rubin also received $21.1K in option awards, $325.1K in salary and $105.5K in other compensation.
Rankings
In 2021, Eyal Rubin's compensation ranked 9,342nd out of 12,406 executives tracked by ExecPay. In other words, Rubin earned more than 24.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 9,342 out of 12,406 | 25th |
Division Manufacturing | 4,140 out of 5,494 | 25th |
Major group Chemicals And Allied Products | 1,825 out of 2,369 | 23rd |
Industry group Drugs | 1,619 out of 2,090 | 23rd |
Industry Biological Products, Except Diagnostic Substances | 357 out of 452 | 21st |
Source: SEC filing on April 29, 2022.
Rubin's colleagues
We found three more compensation records of executives who worked with Eyal Rubin at Protalix BioTherapeutics in 2021.
News
Protalix BioTherapeutics CEO Dror Bashan's 2023 pay jumps 83% to $2.7M
April 29, 2024
Protalix BioTherapeutics CEO Dror Bashan's 2022 pay jumps 27% to $1.5M
May 18, 2023
Protalix BioTherapeutics CEO Dror Bashan's 2021 pay slips 14% to $1.2M
April 29, 2022
Protalix BioTherapeutics CEO Moshe Manor's 2019 pay slips 14% to $616K
April 15, 2020